JUBILANT INGREVIA LIMITED (JUBLINGREA) financials
JUBILANT INGREVIA LIMITED (JUBLINGREA) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceuti…
- Market Cap: ₹10,050Cr.
- Current Price: ₹631
- Stock P/E: 29.1
- ROE: 11.0%
- ROCE: 12.4%
- Book Value: ₹166
- Dividend Yield: 0.79%
- 52W High / Low: ₹795/535
In Jun 2026, JUBILANT INGREVIA LIMITED (JUBLINGREA) reported sales ₹1,253 Cr and net profit ₹126 Cr.
Annual TTM: sales ₹4,418 Cr, net profit ₹335 Cr.
Shareholding: Promoters 45.22% (Sep 2026), FIIs 6.93% (Sep 2026), DIIs 25.18% (Sep 2026), Government 0.02% (Sep 2026), Public 21.69% (Sep 2026).
| Category | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 1,005 | 995 | 972 | 973 | 1,054 | 1,018 | 1,093 | 1,253 |
| Expenses | 878 | 864 | 844 | 852 | 953 | 906 | 956 | 1,039 |
| Operating Profit | 128 | 131 | 128 | 121 | 101 | 112 | 138 | 214 |
| OPM % | 13% | 13% | 13% | 12% | 10% | 11% | 13% | 17% |
| Other Income | 9 | 27 | 36 | 11 | 11 | 20 | 46 | 11 |
| Interest | 17 | 15 | 16 | 15 | 14 | 15 | 13 | 14 |
| Depreciation | 37 | 37 | 37 | 38 | 39 | 42 | 43 | 41 |
| Profit before tax | 82 | 106 | 111 | 79 | 59 | 75 | 128 | 170 |
| Tax % | 27% | 24% | 19% | 26% | 26% | 21% | 18% | 26% |
| Net Profit | 60 | 81 | 90 | 59 | 44 | 60 | 105 | 126 |
| EPS in Rs | 3.78 | 5.06 | 5.64 | 3.70 | 2.76 | 3.75 | 6.61 | 7.92 |
| Raw PDF | — | — | — | — | — | — | — | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 669 | 4,860 | 4,560 | 3,987 | 3,941 | 4,138 | 4,418 |
| Expenses | 0 | 572 | 4,039 | 4,064 | 3,578 | 3,466 | 3,665 | 3,854 |
| Operating Profit | -0 | 97 | 821 | 496 | 409 | 475 | 473 | 565 |
| OPM % | — | 14% | 17% | 11% | 10% | 12% | 11% | 13% |
| Other Income | 0 | -10 | 21 | 30 | 29 | 81 | 86 | 87 |
| Interest | 0 | 9 | 46 | 38 | 66 | 65 | 57 | 56 |
| Depreciation | 0 | 21 | 120 | 120 | 133 | 147 | 161 | 163 |
| Profit before tax | -0 | 56 | 675 | 368 | 239 | 343 | 342 | 432 |
| Tax % | 0% | 31% | 33% | 31% | 32% | 23% | 22% | — |
| Net Profit | -0 | 39 | 452 | 253 | 162 | 263 | 268 | 335 |
| EPS in Rs | -3.40 | 2.42 | 28.39 | 15.91 | 10.20 | 16.54 | 16.82 | 21.04 |
| Dividend Payout % | 0% | 14% | 18% | 31% | 49% | 30% | 30% | — |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 16 | 16 | 16 | 16 | 16 | 16 |
| Reserves | -0 | 1,560 | 1,967 | 2,143 | 2,231 | 2,425 | 2,624 |
| Borrowings | 0 | 782 | 469 | 645 | 870 | 825 | 747 |
| Other Liabilities | 0 | 882 | 1,200 | 1,255 | 1,223 | 1,255 | 1,337 |
| Total Liabilities | 0 | 3,240 | 3,652 | 4,058 | 4,340 | 4,521 | 4,723 |
| Fixed Assets | 0 | 1,727 | 1,728 | 1,775 | 2,292 | 2,335 | 2,366 |
| CWIP | 0 | 65 | 167 | 477 | 181 | 197 | 139 |
| Investments | 0 | 135 | 139 | 172 | 297 | 310 | 327 |
| Other Assets | 0 | 1,313 | 1,619 | 1,635 | 1,571 | 1,679 | 1,892 |
| Total Assets | 0 | 3,240 | 3,652 | 4,058 | 4,340 | 4,521 | 4,723 |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | 104 | 587 | 446 | 394 | 441 | 462 |
| Cash from Investing Activity | 0 | 32 | -221 | -475 | -464 | -211 | -108 |
| Cash from Financing Activity | 0 | -70 | -410 | 33 | 64 | -208 | -230 |
| Net Cash Flow | 0 | 66 | -44 | 3 | -6 | 22 | 124 |
| Free Cash Flow | 0 | 77 | 365 | 3 | 55 | 239 | 335 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0% | 119% | 85% | 104% | 104% | 108% | 116% |
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 51.47% | 51.47% | 45.22% | 45.22% | 45.22% | 45.22% | 45.22% | 45.22% |
| FIIs | 6.89% | 7.12% | 6.96% | 5.96% | 6.15% | 6.49% | 6.49% | 6.93% |
| DIIs | 15.99% | 15.91% | 21.81% | 23.04% | 24.00% | 24.76% | 24.98% | 25.18% |
| Government | 0.00% | 0.00% | 0.00% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Public | 24.90% | 24.76% | 25.30% | 24.94% | 23.80% | 22.53% | 22.30% | 21.69% |
| Others | 0.74% | 0.73% | 0.72% | 0.82% | 0.80% | 0.98% | 0.98% | 0.96% |
| No. of Shareholders | 1,24,830 | 1,20,406 | 1,23,748 | 1,25,749 | 1,17,529 | 1,12,696 | 1,10,949 | 1,09,650 |
| Category | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | — | 262 | 44 | 40 | 52 | 53 | 61 |
| Inventory Days | — | 490 | 97 | 127 | 132 | 141 | 116 |
| Days Payable | — | 649 | 101 | 117 | 129 | 139 | 139 |
| Cash Conversion Cycle | — | 103 | 40 | 50 | 55 | 55 | 38 |
| Working Capital Days | — | 179 | 32 | 23 | 12 | 18 | 10 |
| ROCE % | — | 7% | 30% | 16% | 11% | 13% | 12% |
Jubilant Ingrevia Limited
₹10,050Cr.
₹631
₹795/535
29.1
Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.[1]
Quarterly results
Profit & loss
Shareholding trend
Balance sheet
Cash flows
Key ratios
Frequently asked questions
What is the market cap of JUBILANT INGREVIA LIMITED (JUBLINGREA)?
The reported market capitalisation for JUBILANT INGREVIA LIMITED (JUBLINGREA) is ₹10,050Cr. on Fincrux. Figures may update with market data and filings.
What is the current share price of JUBLINGREA?
The current price shown for JUBILANT INGREVIA LIMITED (JUBLINGREA) on Fincrux is ₹631 with a 52-week high/low of ₹795/535.
What is the P/E ratio of JUBILANT INGREVIA LIMITED (JUBLINGREA)?
The stock P/E for JUBILANT INGREVIA LIMITED (JUBLINGREA) is 29.1 on Fincrux, with ROE at 11.0% and ROCE at 12.4%.
What were JUBLINGREA latest quarterly results?
For Jun 2026, JUBILANT INGREVIA LIMITED (JUBLINGREA) reported sales ₹1,253 Cr and net profit ₹126 Cr (figures in ₹ crore unless noted).
What are JUBLINGREA annual sales and net profit?
For TTM, JUBILANT INGREVIA LIMITED (JUBLINGREA) shows sales of ₹4,418 Cr and net profit of ₹335 Cr on the Fincrux profit & loss statement.
Who owns JUBILANT INGREVIA LIMITED (JUBLINGREA)?
Latest shareholding for JUBILANT INGREVIA LIMITED (JUBLINGREA) on Fincrux: Promoters 45.22% (Sep 2026), FIIs 6.93% (Sep 2026), DIIs 25.18% (Sep 2026), Government 0.02% (Sep 2026), Public 21.69% (Sep 2026).
Where can I find JUBILANT INGREVIA LIMITED (JUBLINGREA) financials?
JUBILANT INGREVIA LIMITED (JUBLINGREA) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.
Does Fincrux show JUBLINGREA balance sheet and cash flow?
Yes. The JUBILANT INGREVIA LIMITED (JUBLINGREA) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.